Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS®) compared with standard interferon alfa-2a.

被引：0
|
作者：
Bernstein, DE
Cooksley, G
Fried, MW
Heathcote, JE
Pockros, PJ
Zeuzem, S
Marinos, G
Rustgi, V
Revicki, D
Barker, CM
Green, J
机构：
[1] N Shore Univ Hosp, Manhasset, NY USA
[2] Royal Brisbane Hosp, Herston, Qld, Australia
[3] Univ N Carolina, Chapel Hill, NC 27515 USA
[4] Univ Toronto, Toronto, ON, Canada
[5] Scripps Clin, La Jolla, CA USA
[6] Univ Hosp, Frankfurt, Germany
[7] Prince Wales Hosp, Randwick, NSW 2031, Australia
[8] Georgetown Univ, Med Ctr, Fairfax, VA USA
[9] MEDTAP Int Inc, Bethesda, MD USA
[10] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
GASTROENTEROLOGY | 2001年 / 120卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1958
引用
收藏
页码：A382 / A382
页数：1
相关论文
共 50 条
  • [1] Enhanced virological response to treatment with 40 kDa peginterferon alfa-2a (PEGASYS®) in patients previously unresponsive to treatment with interferon alfa-2a.
    Minuk, GY
    Reddy, KR
    Lee, SS
    Heathcote, EJ
    O'Grady, J
    Pockros, PJ
    Shiffman, ML
    Naoumov, NV
    Sedarati, F
    Depamphilis, J
    [J]. HEPATOLOGY, 2001, 34 (04) : 330A - 330A
  • [2] Superior virologic response in genotype 4 chronic hepatitis C patients treated with pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with standard interferon.
    Sherman, M
    Dusheiko, GM
    Haeussinger, D
    Marinos, G
    Munoz-Espinoza, L
    Salmeron, J
    DePamphilis, J
    Brunda, MJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [3] Characterization of pegylated (40kDa) interferon alfa-2A (Pegasys™) in the elderly.
    Martin, NE
    Modi, MW
    Reddy, KR
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [4] Therapy with pegylated (40kDa) interferon alfa-2a (Pegasys™) significantly enhances quality of life compared with standard interferon alfa-2za (roferon-A®) in patients with chronic hepatitis C.
    Rasenack, J
    Zeuzem, S
    Feinman, SV
    Heathcote, EJ
    Manns, M
    Yoshida, E
    Swain, MG
    Gane, E
    Diago, M
    Lin, A
    Green, J
    Revicki, D
    [J]. HEPATOLOGY, 2000, 32 (04) : 307A - 307A
  • [5] Enhanced efficacy of pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with interferon alfa-2A (Roferon-A™) for chronic hepatitis C in Blacks.
    Shiffman, ML
    Fromm, H
    Mills, P
    Moonka, DK
    Fried, MW
    Berg, C
    Sherman, M
    Smith, C
    Marsano, L
    Reddy, KR
    Brunda, MJ
    DePamphilis, J
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [6] Pegylated (40KDA) interferon ALFA-2A (Pegasys™) is unaffected by renal impairment.
    Martin, P
    Mitra, S
    Farrington, K
    Martin, NE
    Modi, MW
    [J]. HEPATOLOGY, 2000, 32 (04) : 370A - 370A
  • [7] Clearance of pegylated (40KDA) interferon alfa-2a (Pegasys™) is primarily hepatic.
    Modi, MW
    Fulton, JS
    Buckmann, DK
    Wright, TL
    Moore, DJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 371A - 371A
  • [8] Treatment with 40 kDa peginterferon alfa-2a (PEGASYS®) in combination with ribavirin significantly enhances quality of life compared with interferon alfa-2b plus ribavirin.
    Hassanein, TI
    Cooksley, G
    Sulkowski, M
    Smith, C
    Marinos, G
    Lai, MY
    Pastore, G
    Trejo-Estrada, R
    Vale, AHE
    Lok, AS
    Lin, A
    Green, J
    [J]. HEPATOLOGY, 2001, 34 (04) : 243A - 243A
  • [9] Pegylated (40kDa) interferon alfa-2a (pegasys™) is superior to interferon alfa-2a (roferon-A®) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584.
    Heathcote, EJ
    Balart, LA
    Shiffman, ML
    Pockros, PJ
    Lee, SS
    Reddy, KR
    Minuk, YG
    Bain, V
    Sherman, M
    Wright, TL
    Reindollar, RW
    Brunda, MJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 223A - 223A
  • [10] Prognostic factors and early predictability of sustained viral response (SVR) in patients treated with pegylated (40KDA) interferon ALFA-2A (PEGASYS™):: A new profile.
    Lee, SS
    Heathcote, EJ
    Reddy, KR
    Zeuzem, S
    Fried, MW
    Wright, TL
    Pockros, PJ
    Haeussinger, D
    Smith, C
    Pawlotsky, JM
    Mondor, CHUH
    Lin, A
    Pappas, SC
    [J]. HEPATOLOGY, 2000, 32 (04) : 370A - 370A
12345